Positive Expiratory Pressure for the Treatment of Acute Asthma in Children

University of Colorado Denver (CU Denver)

Status and phase: Completed; Phase 4

Conditions: Asthma

Treatments: Drug: EzPAP; Other: Standard Care

Study type: Interventional

Funder types: Other

Identifiers

NCT02494076

14-1106

Details and patient eligibility

About

Asthma is a leading cause of emergency department (ED) visits for children. A novel way of treating asthma is the use of positive expiratory pressure (PEP). Positive expiratory pressure works by creating pressure in the lungs to keep airways open and to clear mucus from the lungs. PEP is already used in the treatment of asthma at the investigators institution, but studies evaluating the efficacy of PEP therapy in asthma exacerbations do not exist. This study plans to learn more about the use of PEP therapy in the treatment of asthma exacerbations in children in the emergency department. Specifically, the study aims to evaluate if PEP therapy reduces the severity of asthma exacerbations in children and if it reduces the need for additional therapies and admission to the hospital. This study will be a randomized control trial comparing children who receive standard therapy to those who receive standard therapy plus PEP therapy in the treatment of asthma exacerbations. Children age 2 to 18 years presenting to the ED with moderate to severe asthma exacerbations will be included in the study. Reduction in clinical asthma severity will be measured by change in the Pulmonary Asthma Score (the respiratory severity score used at the investigators institution). The need for additional therapies and hospitalization will also be evaluated.

Enrollment: 52 patients

Sex: All

Ages: 2 to 18 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Age >= 2 and < 18 years of age
• Established diagnosis of asthma, defined as at least two prior episodes of treatment with bronchodilators in their lifetime
• Initial ED presentation with a moderate to severe asthma exacerbation, as defined by a pulmonary asthma score (PAS) >7
• PAS score >7 and <12 after completion of first line therapies (three doses albuterol/ipratropium bromide and oral corticosteroids)

Exclusion criteria

• Do not receive complete first line therapies
• Immediately receive a disposition (admission or discharge) as determined by the treating clinician after completion of first line therapies
• Receive prednisone or more than two doses of inhaled bronchodilators prior to main ED evaluation (e.g. during EMS transport or primary care visit)
• Co-morbid illnesses interfering with or contraindicated to usual asthma therapy (e.g. facial or airway abnormalities, pneumonia, chronic lung disease, congenital heart disease, cystic fibrosis, or pneumothorax)
• Critically ill at presentation
• Pregnant women (women known to be pregnant at the time of enrollment)

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Single Blind

---

52 participants in 2 patient groups

EzPAP

Experimental group

Description:

Patients randomized to the EzPAP arm will receive first-line therapies and PEP therapy via EzPAP. All patients will receive 4 cycles with 12 breaths per cycle. 4 cycles is considered one time administration.

Treatment:

Drug: EzPAP

Standard care

Sham Comparator group

Description:

Patients randomized to the control arm will receive first-line therapies and standard therapy.

Treatment:

Other: Standard Care